Phase 3 Trial Shows Superior Survival With Rilertinib for EGFR-Mutated NSCLC

© 2024 Mashup Media, LLC. All rights reserved.

Highlighted Terms

NSCLCRilertinib
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy